A. Is the only 4th generation cephalosporin B. Is more resistant to B-lactamase and can only be given parenterally C. Has antipseudomonal activity and has better G+ coverage D. Is excreted renally E. All of the above
Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity than the third-generation agents against Gram-positive and Gram-negative bacteria, with greater activity against both types of organisms.
In a meta-analysis held in 2007, suggestions were made on how data of trials were combined. Mortality was increased in people who treated with cefepime compared with other β-lactam antibiotics. The United State Food and Drug Administration in response, performed their own meta-analysis which did not find any mortality difference.
Bristol-Myers Squibb developed Cefepime and was marketed in the beginning of 1994. It is now available as a generic drug and sold under a variety of trade names nationwide.